1. Market Research
  2. > Healthcare
  3. > Medical Supply Market Trends
Analysis of the Global Fibrinogen Market and Product Pipeline

Analysis of the Global Fibrinogen Market and Product Pipeline

  • December 2015
  • 54 pages
  • ID: 3471851
  • Format: PDF
  • Frost & Sullivan

Summary

Table of Contents

The increased demand for fibrinogen and the development of innovative delivery systems such as sprays and patches are fuelling the growth of the fibrinogen market. This research service provides a detailed assessment of the global fibrinogen market, covering the current market scenario and growth prospects for the period 2015–2020. Both marketed and pipeline products are segmented based on their therapeutic uses, namely, deficiency therapy and operative care. An elaborate discussion on clinical trial timelines and results, along with historical and projected launch timelines, has been provided. The study also discusses key companies such as CSL Behring, LFB, Baxter Healthcare, Takeda, Grifols, and Octapharma.

Executive Summary—Key Findings
• Fibrinogen and fibrin products combined account for % of the total blood plasma market, equal to
$ billion in 2015. This is expected to grow at a modest rate of % to reach $ billion in 2020.
• The growth rate is driven by the increase in innovation and the development of spray-type fibrinogen and fibrin concentrate, powdered fibrin concentrate, transparent fibrinogen concentrate/fibrin adhesives in the area of operative care as a surgical adjunct to control blood loss associated with bleeding.
• Anticoagulants and other artificial coagulation products pose a threat to market growth. Further, pricing pressure for blood plasma product providers are mitigating the entry of new participants, although the commercial potential of these products is promising.
• The market is dominated by the top blood plasma product providers CSL Behring and LFB Group, while Biotest, Octapharma, and Grifols are venturing to make their footprint in the market.
• Others include key stakeholders supplying these products to pharmaceutical companies (e.g., Takeda, The Medicines Company), and medical technologies and consumable manufacturers (e.g., Ethicon, Healthpoint) engaged in providing surgical wound adhesives coated with fibrinogen/fibrin.
• There are at least approved fibrinogen concentrates for fibrinogen deficiency, and 10 fibrin/fibrinogen products for controlling bleeding during surgeries. Key products include Haemocomplettan (CSL Behring), Clottafact (LFB), Artiss (Baxter Healthcare), EVARREST (Ethicon), Tisseel (Baxter Healthcare), and Beriplast P (CSL Behring).
• 15 more clinical trials are being conducted across the globe to treat deficiency diseases/disorders and for operative/surgical care. Most of these clinical trials are conducted for approved products to expand their application for different operative care (e.g., cardiac surgery, venous ulcers).
• The key promising candidates in the clinical development include the following:
o Haemocomplettan is a fibrinogen concentrate available as a powder for solution or as an
infusion for intravenous administration. It is approved for fibrinogen deficiency. It is also being
evaluated for cardiac surgery, in Phase 2/3, to address bleeding associated with coagulopathy
bleeding.
o Fibrin Sealant (FS) Grifols is a fibrinogen and thrombin concentrate assembled on a syringe
holder and applied topically on the bleeding site. It is in Phase 3 clinical trials as an adjunct to
haemostasis during soft-tissue open surgeries and parenchymous-tissue open surgeries.
o Octafibrin is being developed by Octapharma. It is a plasma-derived, highly purified,
lyophilized fibrinogen concentrate that has been double-virus safeguarded using two dedicated
virus inactivation/removal steps. Octafibrin is evaluated for both congenital fibrinogen
deficiency and as a surgical adjunct in operative care.
• Other key pivotal products in development include FCH (CSL Behring) and HP802-247
(Healthpoint). In April 2015, the FDA approved Raplixa (Fibrocaps) developed by Profibrix (acquired
by The Medicines Company) to control bleeding during surgery.
• The forecast period is expected to witness the launch of key products such as FCH (CSL Behring),
FS Grifols (Grifols), FIB (Grifols), Octafibrin (Octapharma), HP802-247 (Healthpoint), and BT-524
(Biotest).

Methodology and Scope
• This research service focuses on the global fibrinogen market and offers an overview of therapeutics for deficiency therapies and operative care. The market includes fibrinogen and fibrin products. A product and pipeline assessment is provided for marketed and investigational fibrinogen and fibrin products. The study covers the application of fibrinogen for deficiency therapies and operative care (surgical adjuncts).
• Products that have failed, been terminated/suspended/recalled have not been covered. No fibrin or fibrinogen stimulants, fibrinolytics and clotting factors involved in fibrinolysis are covered.
• The information contained in this research service was derived from published sources, including the following:
o Disease organization Web sites
o Clinical Trials.gov
o Company publications, including annual reports
o Securities and Exchange Commission (SEC) filings
o Press releases
o US government public sources
o Published articles in scientific journals
• Fibrinogen is a plasma glycoprotein with a molecular weight of kDa and is synthesized by the liver.
It is associated with the clotting of blood during haemorrhages or vascular injuries forming fibrin strands through proteolysis by the enzyme thrombin.
• Fibrinogen and fibrin together form part of the blood plasma market—which includes immunoglobulin, fibrinogen, alpha trypsin, Factor VIII, and thrombin—and finds application in the treatment of fibrinogen deficiencies and control of bleeding during surgeries, i.e., as a surgical adjunct.
• It is estimated that one in a million population are affected by fibrinogen deficiency. It has been
classified as a rare deficiency disease/orphan disease.
• Native fibrinogen is derived from the blood by fractionation and by recombinant methods. Large blood plasma product providers (CSL Behring), biopharmaceutical companies (Baxter Healthcare), contract manufacturers, and medical technologies and consumable manufacturers engage in providing fibrinogen and fibrin products.
• There has been an increase in innovative technologies. Spray-based fibrin bandages and transparent bandage adhesives are in clinical development.
• At present, there are only approved products for fibrinogen deficiency and 10 products for controlling bleeding during surgeries. Key products include Haemocomplettan (CSL Behring), Clottafact (LFB), Artiss (Baxter Healthcare), Evarrest (Ethicon), Tisseel (Baxter Healthcare), and Beriplast P(CSL Behring).
• Many of these approved products are also being evaluated for other surgical indications to expand their scope of application in operative care. The market is expected to grow at a modest CAGR rate of % to reach $ billion in 2020.

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 150+ Million searchable statistics with tables, figures & datasets
  • More than 25,000 trusted sources
  • Single User License — provides access to the report by one individual.
  • Department License — allows you to share the report with up to 5 users
  • Site License — allows the report to be shared amongst all employees in a defined country
  • Corporate License — allows for complete access, globally.

ReportLinker may already be registered as a supplier with your company. If you want to Order by PO, check with us first and we'll let you know if we are a registered supplier and what the vendor number is. Otherwise, we'll provide you with the necessary information to register ReportLinker as a vendor.

Ahmad helps you find the right report:
Testimonials

The research specialist advised us on the best content for our needs and provided a great report and follow-up, thanks very much we shall look at ReportLinker in the future.

Kate Merrick

Global Marketing Manager at
Eurotherm by Schneider Electric

We were impressed with the support that ReportLinker’s research specialists’ team provided. The report we purchased was useful and provided exactly what we want.

Category Manager at
Ikea

ReportLinker gave access to reliable and useful data while avoiding dispersing resources and spending too much time on unnecessary research.

Executive Director at
PwC Advisory

The customer service was fast, responsive, and 100% professional in all my dealings (...) If we have more research needs, I'll certainly prioritize working with ReportLinker!

Scott Griffith

Vice President Marketing at
Maurice Sporting Goods

The research specialist provided prompt, helpful instructions for accessing ReportLinker's product. He also followed up to make sure everything went smoothly and to ensure an easy transition to the next stage of my research

Jessica P Huffman

Research Associate at
American Transportation Research Institute

Excellent customer service. Very responsive and fast.

Director, Corporate Strategy at
Ingredion

I reached out to ReportLinker for a detailed market study on the Air Treatment industry. The quality of the report, the research specialist’s willingness to solve my queries exceeded my expectations. I would definitely recommend ReportLinker for in-depth industry information.

Mariana Mendoza

Global Platform Senior Manager at
Whirlpool Corporation

Thanks! I like what you've provided and will certainly come back if I need to do further research works.

Bee Hin Png

CEO at
LDR Pte Ltd

The research specialist advised us on the best content for our needs and provided a great report and follow-up, thanks very much we shall look at ReportLinker in the future.

Kate Merrick

Global Marketing Manager at
Eurotherm by Schneider Electric

FAQ
  • How we can help
    • I am not sure if the report I am interested in will fulfill my needs. Can you help me?
    • Yes, of course. You can call us at +33(0) 4 37 65 17 03 or drop us an email at [email protected] to let us know more about your requirements.
    • We buy reports often - can ReportLinker get me any benefits?
    • Yes. Set up a call with a Senior Research Advisor to learn more - [email protected] or +33(0) 4 37 65 17 03.
    • I have had negative experiences with market research reports before. How can you avoid this from happening again?
    • We advise all clients to read the TOC and Summary and list your questions so that we can get more insight for you before you make any purchase decision. A research advisor will accompany you so that you can compare samples and reports from different sources, and choose the study that is right for you.

  • Report Delivery
    • How and when I will receive my Report?
    • Most reports are delivered right away in a pdf format, while others are accessed via a secure link and access codes. Do note that sometimes reports are sent within a 12 hour period, depending on the time zones. However, you can contact us to escalate this. Should you need a hard copy, you can check if this option is offered for the particular report, and pay the related fees.
  • Payment conditions
    • What payment methods do you accept?
      1. Credit card : VISA, American Express, Mastercard, or
      2. You can download an invoice to pay by wire transfer, check, or via a Purchase Order from your company, or
      3. You can pay via a Check made out in US Dollars, Euros, or British Pounds for the full amount made payable to ReportLinker
    • What are ReportLinker’s Payment Terms?
    • All payments must normally be submitted within 30 days. However, you can let us know if you need extended time.
    • Are Taxes and duties included?
    • All companies based in France must pay a 20% tax per report. The same applies to all individuals based in the EU. All EU companies must supply their VAT number when purchasing to avoid this charge.
    • I’m not satisfied. Can I be refunded?
    • No. Once your order has been processed and the publisher has received a notification to send you the report, we cannot issue any refund or cancel any order. As these are not ‘traditional’ products that can be returned, reports that are dispatched are considered to be ‘consumed’.
  • User license
    • The license that you should acquire depends on the number of persons that need to access the report. This can range from Single User (only one person will have the right to read or access the report), or Department License (up to 5 persons), to Site License (a group of persons based in the same company location), or Corporate License (the entire company personnel based worldwide). However, as publishers have different terms and conditions, we can look into this for you.
Purchase Reports From Reputable Market Research Publishers

ref:plp2015

Reportlinker.com © Copyright 2021. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.

Make sure you don’t miss any news and follow us on